Ina Khachatryan, Assistant Managing Editor at OncoDaily Medical Journal, shared a post on LinkedIn:
“New Comprehensive Review on Next-Gen CAR and TCR T-Cells Against Tumor Resistance published in OncoDaily Medical Journal by Mane Tavadyan.
This review examines how next-generation CAR and TCR T-cell therapies are being engineered to overcome major resistance barriers in cancer treatment. While adoptive cell therapy has transformed outcomes in hematologic malignancies, its success in solid tumors is limited by antigen escape, immunosuppressive microenvironments, metabolic stress, T-cell exhaustion, and poor trafficking.
The author highlights cutting-edge strategies including:
- Multi-antigen and logic-gated CARs to prevent tumor escape
- Armored and metabolically enhanced T-cells to resist suppressive TMEs
- TCR-mimic and affinity-tuned receptors for broader antigen recognition
- AI-assisted receptor optimization, tumor-on-chip systems, and advanced manufacturing”
Title: Engineering CAR and TCR T-Cells to Overcome Resistance in Cancer Therapy
Author: Mane Tavadyan
Read the Full Article on ODMJ
More posts featuring OncoDaily Medical Journal.
